Pathology and pathophysiology of drug-induced arterial injury in laboratory animals and its implications on the evaluation of novel chemical entities for human clinical trials.
about
Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injuryChronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents.Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.The Far Side of Vascular Injury: Nonconventional Vasoconstrictors, DNA-targeting Agents, and Agents Toxic to Vascular Smooth Muscle.Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.A bilayer small diameter in vitro vascular model for evaluation of drug induced vascular injuryEvidence for the nitric oxide pathway as a potential mode of action in fenoldopam-induced vascular injury.Gene expression analysis of the acute phase response using a canine microarray.Coronary and systemic arterial physiology and immunohistochemical markers related to early coronary arterial lesions in beagle dogs given the potassium channel opener, ZD6169, or the endothelin receptor antagonist, ZD1611.Novel vascular lesions in mice given a non-peptide vitronectin receptor antagonist.Naphthoquine-induced Central Nervous System and Hepatic Vasculocentric Toxicity in the Beagle Dog.Translation strategy for the qualification of drug-induced vascular injury biomarkers.
P2860
Q34466077-244148FE-7552-4FD6-B882-AF427A954738Q37154338-149A0CE9-3B1A-4AB9-83B5-BC3CC948DE49Q38365744-6BAF974F-B2E8-4381-B163-AB0887823EACQ38583684-942861F8-7F54-4A1F-AD3E-6D8C26566322Q39201920-4BEEEE7B-74C3-4B75-8414-B4792D01F893Q42178673-241473EE-7F74-4785-A298-0E8C0B8BDDB2Q44152031-F40263D5-07EE-4A80-B065-4299BA06F8BEQ44457985-03D57D28-F7D0-4CA0-9BEE-EF1FC0E79F5DQ45169346-14FA0011-5375-4EE8-89C8-89F8268A99AAQ46837495-575A8485-7493-4AAD-AF3C-1C96846915C7Q47949963-F0E07659-78ED-41C8-9F6D-8A87D79CDC70Q51739310-DBA113E0-B67A-4DA5-A122-CE82B7E0FE00
P2860
Pathology and pathophysiology of drug-induced arterial injury in laboratory animals and its implications on the evaluation of novel chemical entities for human clinical trials.
description
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im Oktober 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in 2001
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2001
@uk
২০০১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ
@bn
name
Pathology and pathophysiology ...... ies for human clinical trials.
@ast
Pathology and pathophysiology ...... ies for human clinical trials.
@en
Pathology and pathophysiology ...... ies for human clinical trials.
@nl
type
label
Pathology and pathophysiology ...... ies for human clinical trials.
@ast
Pathology and pathophysiology ...... ies for human clinical trials.
@en
Pathology and pathophysiology ...... ies for human clinical trials.
@nl
prefLabel
Pathology and pathophysiology ...... ies for human clinical trials.
@ast
Pathology and pathophysiology ...... ies for human clinical trials.
@en
Pathology and pathophysiology ...... ies for human clinical trials.
@nl
P1476
Pathology and pathophysiology ...... ies for human clinical trials.
@en
P2093
P304
P356
10.1111/J.0901-9928.2001.890404.X
P577
2001-10-01T00:00:00Z